MedTrace Logo

Brentuximab for Newly Diagnosed Hodgkin Disease

NCT02398240 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-10-26

No results posted yet for this study

Summary

The addition of Brentuximab vedotin (Bv) to combination chemotherapy will be safe, well tolerated and effective in children, adolescents and young adults with all stages of newly diagnosed Hodgkin lymphoma (HL).

Conditions

Interventions

DRUG

Brentuximab Vedotin

Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)

DRUG

Doxorubicin

Days: 1 and 15 Dose: 25 mg/m2/dose.

DRUG

Vincristine

Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).

DRUG

Rituximab

Days: 2 and 16 Dose: 375 mg/m2/dose.

Sponsors & Collaborators

  • Mitchell Cairo

    lead OTHER

Principal Investigators

  • Jessica Hochberg, MD · New York Medical College

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
29 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2022-06-30
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02398240 on ClinicalTrials.gov